Business Context and Reporting Period
This Form 8-K filing by RXi Pharmaceuticals Corporation (referred to as Phio Pharmaceuticals Corp. in metadata) covers events occurring on June 18, 2012, and June 19, 2012. The report details the appointment of two new members to the Company's Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and executive compensation arrangements.
Material Changes
The primary material change is the expansion of the Board of Directors with the appointment of Keith L. Brownlie and Robert J. Bitterman, effective June 18 and June 19, 2012, respectively. Their terms are set to last until the 2013 annual meeting of stockholders. Committee assignments for the new directors have not yet been determined.
Management Commentary and Compensation Arrangements
The Company entered into agreements with the new directors outlining the following compensation structure:
- Annual Retainer: $20,000 per director, payable in quarterly installments of $5,000.
- Initial Option Grant: A one-time grant for up to 1,000,000 shares of common stock per director, vesting quarterly over one year under the 2012 Incentive Plan.
- Future Option Grants: Commencing in 2013, an annual grant for up to 500,000 shares of common stock per director, vesting quarterly over one year.
- Expenses: Reimbursement for travel and reasonable out-of-pocket expenses.
Investor Verification Checklist
- Verify the total number of shares authorized under the 2012 Incentive Plan to assess the dilution impact of the 2,000,000 initial option grants.
- Confirm the vesting schedule details and any performance conditions attached to the option grants.
- Review the Company's cash position to ensure it can meet the quarterly retainer obligations.
- Monitor future filings for the assignment of the new directors to specific Board committees.